After more than 25 years of development, arthritis gene therapy is finally entering clinical practice. In South Korea, a gene therapeutic has been approved for the treatment of osteoarthritis, and other gene therapeutics are in the pipeline elsewhere. Genetic medicines for arthritis should enter the rheumatological armamentarium in the foreseeable future.
This is a preview of subscription content, log in via an institution to check access.
References
US Food and Drug Administration. Approved cellular and gene therapy products. US Food and Drug Administration. FDA https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/default.htm (2018).
Evans, C. H., Ghivizzani, S. C. & Robbins, P. D. Gene delivery to joints by intra-articular injection. Hum. Gene Ther. 29, 2–14 (2018).
Watson, R. S. et al. scAAV-mediated gene transfer of interleukin-1 receptor antagonist to synovium and articular cartilage in large mammalian joints. Gene Ther. 20, 670–677 (2013).
Ruan, M. Z. et al. Proteoglycan 4 expression protects against the development of osteoarthritis. Sci. Transl Med. 5, 176ra134 (2013).
Kim, M. K. et al. A multicenter, double-blind, phase III clinical trial to evaluate the efficacy and safety of a cell and gene therapy in knee osteoarthritis patients. Hum. Gene Ther. Clin. Dev. https://doi.org/10.1089/hum.2017.249 (2018).
Cherian, J. J. et al. Preliminary results of a phase II randomized study to determine the efficacy and safety of genetically engineered allogeneic human chondrocytes expressing TGF-β in patients with grade 3 chronic degenerative joint disease of the knee. Osteoarthritis Cartilage 23, 2109–2118 (2015).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02790723 (2017).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02727764 (2018).
Acknowledgements
The work of C.H.E., S.C.G. and P.D.R. in this area has been funded by multiple grants from the National Institute of Arthritis and Musculoskeletal Skin Diseases (NIAMS) and the National Institute on Aging (NIA) and the US Department of Defense.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
C.H.E and P.D.R. declare that they are on the scientific advisory board of TissueGene Inc. S.C.G declares no competing interests
Rights and permissions
About this article
Cite this article
Evans, C.H., Ghivizzani, S.C. & Robbins, P.D. Arthritis gene therapy is becoming a reality. Nat Rev Rheumatol 14, 381–382 (2018). https://doi.org/10.1038/s41584-018-0009-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-018-0009-5
- Springer Nature Limited
This article is cited by
-
The therapeutic potential of immunoengineering for systemic autoimmunity
Nature Reviews Rheumatology (2024)
-
LOXL2 promotes aggrecan and gender-specific anabolic differences to TMJ cartilage
Scientific Reports (2020)
-
Biological perspectives and current biofabrication strategies in osteochondral tissue engineering
Biomanufacturing Reviews (2020)
-
Spine Disorders and Regenerative Rehabilitation
Current Physical Medicine and Rehabilitation Reports (2020)
-
Biomaterial-guided delivery of gene vectors for targeted articular cartilage repair
Nature Reviews Rheumatology (2019)